<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801073</url>
  </required_header>
  <id_info>
    <org_study_id>0060 / 04</org_study_id>
    <nct_id>NCT00801073</nct_id>
  </id_info>
  <brief_title>Comparison Amongst Scleral, Corneal and Amniotic Membrane Grafts to Restore Scleral Thinning</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of S達o Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of preserved scleral, corneal and amniotic&#xD;
      membrane graft for the surgical repair of scleral thinning of different sizes in patients&#xD;
      underwent surgery of pterygium with associated beta therapy .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scleral thinning may occur secondary to different ocular surface conditions, especially in&#xD;
      rheumatologic diseases and after surgeries as in pterygium. There are different methods to&#xD;
      treat this condition, as to use scleral, corneal and more recently amniotic membrane graft.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The surgical procedure was randomized in scleral, corneal or amniotic membrane graft. Nine patients underwent surgery with scleral graft that was covered by conjunctival flap; ten with corneal graft and ten with amniotic membrane transplantation.</measure>
    <time_frame>Patients were followed for 180 days.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Scleral Thinning</condition>
  <arm_group>
    <arm_group_label>Amniotic Membrane Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Human Amniotic Membrane Transplantation</intervention_name>
    <description>Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease</description>
    <arm_group_label>Amniotic Membrane Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with corneal scleral defects that have persisted for 1 years or longer,&#xD;
             regardless of their cause. These patients will have received corneal-scleral or&#xD;
             amniotic membrane transplant in order to correct scleral thinning&#xD;
&#xD;
          -  Patients with history of pterygium surgery associated with beta therapy followed by&#xD;
             scleral thinning&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular infection&#xD;
&#xD;
          -  Acute ocular inflammatory condition&#xD;
&#xD;
          -  Previous ocular surgery in the eye study&#xD;
&#xD;
          -  Non-controlled systemic disease such as rheumatoid arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jose Alvaro Pereira Gomes</name_title>
    <organization>Departamento de Oftalmologia/Instituto da Vis達o, Universidade Federal de S達o Paulo (UNIFESP), Brazil</organization>
  </responsible_party>
  <keyword>Amniotic membrane</keyword>
  <keyword>Cornea</keyword>
  <keyword>Scleral thinning</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

